Skip to content

The Effect of Oliceridine on Postoperative Cerebral Function in Patients Undergoing Gastrointestinal Tumor Resection for Postoperative Analgesia: A Single-Center, Randomized, Double-Blind, Controlled Study

The Effect of Oliceridine on Postoperative Cerebral Function in Patients Undergoing Gastrointestinal Tumor Resection for Postoperative Analgesia: A Single-Center, Randomized, Double-Blind, Controlled Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114668
Enrollment
Unknown
Registered
2025-12-16
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal tumor

Interventions

Sponsors

Affiliated Hospital of Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age >=65 years; 2. Patients scheduled for primary elective laparoscopic radical resection of gastrointestinal cancer under general anesthesia. 3. Postoperative length of stay >= 3 days.

Exclusion criteria

Exclusion criteria: 1. Preoperatively unable to communicate due to cognitive impairment or language impairment; 2. Preoperative history of chronic pain or opioid abuse; 3. A history of drug abuse and/or alcohol abuse within the past 3 months; 4. Patients who are expected to be unable to assess pain intensity postoperatively or transferred to the ICU; 5. Abnormal liver and renal function; 6. Patients who have contraindications to or are allergic to the study drugs (oliceridine, sufentanil) and other related drugs; 7. Patients with respiratory depression or those at high risk of respiratory depression (e.g., obstructive sleep apnea syndrome); 8. Patients with craniocerebral injury, possible intracranial hypertension, cerebral aneurysm, history of cerebrovascular accident, or suffering from central nervous system diseases (e.g., epilepsy); 9. Patients with mental system diseases (e.g., depression) or those on long-term use of psychotropic drugs; 10. Electrocardiogram (ECG) shows QT interval prolongation; 11. Patients who have participated in clinical studies of other drugs or medical devices within the past 3 months.

Design outcomes

Primary

MeasureTime frame
Incidence and severity of postoperative delirium;

Secondary

MeasureTime frame
Incidence of adverse events;short-term and long-term postoperative cognitive function;Postoperative sleep quality;Postoperative sedation score;Postoperative quality of recovery;Rescue analgesic usage;Postoperative biochemical indicators;Gastrointestinal reactions;Pain Scores;

Countries

China

Contacts

Public ContactJiru Zhang

Affiliated Hospital of Jiangnan University

zjr2010508@126.com+86 510 6808 9310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026